Skip to main content
padlock icon - secure page this page is secure

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Buy Article:

$52.00 + tax (Refund Policy)

The E-VITA study evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer. This multicenter, open-label phase II trial, randomly assigned patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer to lapatinib 1000 mg daily with eribulin 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) days 1+8 every 21 days (split-dose arm) or eribulin 1.76 mg/m2 (equivalent to 2.0 mg/m2 eribulin mesylate) day 1 every 21 days (3-weekly arm). Time to progression and tolerability were defined as primary end points; no sample size calculation for formal comparison of efficacy data has been performed. Secondary end points included objective response rate, clinical benefit rate, and overall survival. Overall, 43 patients of a planned number of 80 patients were recruited. At a median follow-up of 28.7 months, the median time to progression was 8.1 months [95% confidence interval (CI): 4.8–9.4] in the split-dose arm and 6.5 months (95% CI: 4.6–13.4) in the 3-weekly arm. Objective response rate was 52.4% (95% CI: 31.0–73.7) in the split-dose arm and 45.0% (95% CI: 23.2–66.8) in the 3-weekly arm, and clinical benefit rate was 71.4% (95% CI: 52.1–90.8) and 75.0% (95% CI: 56.0–94.0), respectively. Overall survival was also similar in both arms. The most frequent grade 3–4 adverse events were neutropenia (58.5%) and leukopenia (39.0%). The combination of eribulin and lapatinib showed an acceptable safety profile with less toxicity observed in the eribulin 1.23 mg/m2 day 1+8 group. This might be an alternative regimen when other treatment options are exhausted. Therefore, further clinical studies are warranted.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: HER-2-positive; breast cancer; eribulin; lapatinib

Document Type: Research Article

Affiliations: 1: Women’s Hospital, Städtisches Klinikum Dessau 2: Women’s Hospital, Agaplesion Markus-Krankenhaus, Frankfurt am Main, Gynaecological Hospital, Charité Universitätsmedizin Berlin 3: University Women’s Hospital Kiel, UK-SH, Kiel 4: University Women’s Hospital Magdeburg, Otto-von Guericke-Universität, Magdeburg 5: University Women’s Hospital Würzburg 6: Breast Center, Diakovere Henriettenstiftung, Hannover 7: National Center for Tumor Diseases, University Hospital Heidelberg 8: German Breast Group, Neu-Isenburg 9: Women’s Hospital, University Hospital Tübingen 10: Women’s Hospital, UKE University Hospital Hamburg-Eppendorf KMTZ, Hamburg 11: Women’s Hospital, University Medical Center Mainz 12: Women’s Hospital, University Hospital Rostock 13: Women’s Hospital, Kliniken Essen Mitte Evang. Huyssens-Stiftung, Essen 14: Breast Center, St. Elisabeth Krankenhaus Hohenlind, Cologne 15: Women’s Hospital, Klinikum Chemnitz, Germany 16: Women’s Hospital, Agaplesion Markus-Krankenhaus, Frankfurt am Main

Publication date: April 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more